Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects

References

• Cannata-Andia JB, Martin-Carro B, Martin-Virgala J, et al. Chronic Kidney Disease-Mineral and Bone Disorders: pathogenesis and Management. Calcif Tissue Int. 2021;108(4):410–422. doi:10.1007/s00223-020-00777-1
   PubMed Web of Science ®Google Scholar
• Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–1953. doi:10.1038/sj.ki.5000414
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Shilov E, Li Z, et al. Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America. Adv Ther. 2020;37(6):2748–2762. doi:10.1007/s12325-020-01359-1
   PubMed Web of Science ®Google Scholar
• Hedgeman E, Lipworth L, Lowe K, et al. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. 2015;2015:184321. doi:10.1155/2015/184321
   PubMedGoogle Scholar
• Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913–921. doi:10.2215/CJN.06040710
   PubMed Web of Science ®Google Scholar
• Cianciolo G, Capelli I, Cappuccilli M, et al. Calcifying circulating cells: an uncharted area in the setting of vascular calcification in CKD patients. Clin Kidney J. 2016;9(2):280–286. doi:10.1093/ckj/sfv145
   PubMed Web of Science ®Google Scholar
• Wang J, Bieber BA, Hou FF, Port FK, Anand S. Mineral and bone disorder and management in the China Dialysis Outcomes and Practice Patterns Study. Chin Med J (Engl). 2019;132(23):2775–2782. doi:10.1097/CM9.0000000000000533
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59. doi:10.1016/j.kisu.2017.04.001
   PubMed Web of Science ®Google Scholar
• Evenepoel P. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int. 2008;74(3):265–275. doi:10.1038/ki.2008.166
   PubMed Web of Science ®Google Scholar
• Drueke TB. Calcimimetics and outcomes in CKD. Kidney Int Suppl. 2013;3(5):431–435. doi:10.1038/kisup.2013.90
   Web of Science ®Google Scholar
• Pereira L, Meng C, Marques D, Frazao JM. Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J. 2018;11(1):80–88. doi:10.1093/ckj/sfx125
   PubMed Web of Science ®Google Scholar
• Martin KJ, Pickthorn K, Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85(1):191–197. doi:10.1038/ki.2013.289
   PubMed Web of Science ®Google Scholar
• Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: a New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial. 2020;24(3):248–257. doi:10.1111/1744-9987.13434
   PubMed Web of Science ®Google Scholar
• Investigators ET, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–2494. doi:10.1056/NEJMoa1205624.
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303–311. doi:10.2165/00003088-200948050-00002
   PubMed Web of Science ®Google Scholar
• Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet. 2007;46(6):495–501. doi:10.2165/00003088-200746060-00003
   PubMed Web of Science ®Google Scholar
• Kumar GN, Sproul C, Poppe L, et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos. 2004;32(12):1491–1500. doi:10.1124/dmd.104.000604
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ortiz ME, Rodriguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Res. 2020;9:1077. doi:10.12688/f1000research.22636.1
   Google Scholar
• Block GA, Bushinsky DA, Cheng S, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: a Randomized Clinical Trial. JAMA. 2017;317(2):156–164. doi:10.1001/jama.2016.19468
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Van Wagenen BC, Balandrin MF. Discovery and Development of Calcimimetic and Calcilytic Compounds. Prog Med Chem. 2018;57(1):1–86. doi:10.1016/bs.pmch.2017.12.001.
   PubMedGoogle Scholar
• Fukagawa M, Shimazaki R, Akizawa T. Evocalcet study g. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018;94(4):818–825. doi:10.1016/j.kint.2018.05.013
   PubMed Web of Science ®Google Scholar
• Kawata T, Tokunaga S, Murai M, et al. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018;13(4):e0195316. doi:10.1371/journal.pone.0195316
   PubMed Web of Science ®Google Scholar
• Akizawa T, Shimazaki R, Fukagawa M, Evocalcet Study G. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: a randomized, double-blind, placebo-controlled, dose-finding study. PLoS One. 2018;13(10):e0204896. doi:10.1371/journal.pone.0204896
   PubMed Web of Science ®Google Scholar
• Ni Z, Liang X, Wu CC, et al. Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism. Kidney Int Rep. 2023;8(11):2294–2306. doi:10.1016/j.ekir.2023.08.034
   PubMed Web of Science ®Google Scholar
• Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: first-in-Human Phase I Study. Clin Drug Investig. 2018;38(10):945–954. doi:10.1007/s40261-018-0687-4
   PubMed Web of Science ®Google Scholar
• Zuo L, Wang M. Chinese Association of Blood Purification Management of Chinese Hospital A. Current burden and probable increasing incidence of ESRD in China. Clin Nephrol. 2010;74(Suppl 1):S20–22.
   PubMedGoogle Scholar
• Zhang L, Zuo L. Current burden of end-stage kidney disease and its future trend in China. Clin Nephrol. 2016;86(13):27–28. doi:10.5414/CNP86S104
   PubMedGoogle Scholar
• Hamano N, Endo Y, Kawata T, Fukagawa M. Development of evocalcet for unmet needs among calcimimetic agents. Expert Rev Endocrinol Metab. 2020;15(5):299–310. doi:10.1080/17446651.2020.1780911
   PubMed Web of Science ®Google Scholar
• Liu H, Wang H, Liu T, et al. Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: a Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. Clin Ther. 2016;38(2):348–357. doi:10.1016/j.clinthera.2015.12.015
   PubMed Web of Science ®Google Scholar
• Berlyne GM, Ari JB, Danovitch GM, Blumenthal M. Cataracts of chronic renal failure. Lancet. 1972;1(7749):509–511. doi:10.1016/S0140-6736(72)90175-4
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang L, Xie J, Zhao M, Liu X. Hypocalcemic cataract secondary to idiopathic hypoparathyroidism in an adolescent. J Int Med Res. 2023;51(8):3000605231193820. doi:10.1177/03000605231193820
   Web of Science ®Google Scholar
• Daba KT, Weldemichael DK, Mulugeta GA. Bilateral hypocalcemic cataract after total thyroidectomy in a young woman: case report. BMC Ophthalmol. 2019;19(1):233. doi:10.1186/s12886-019-1224-9
   PubMed Web of Science ®Google Scholar
• Jafari R, Kamali M, Rad MM. A new pattern of bilateral cataracts associated with hypocalcemia secondary to uncontrolled hypoparathyroidism. Oman J Ophthalmol. 2022;15(3):389–392. doi:10.4103/ojo.ojo_238_21
   PubMedGoogle Scholar
• Hannan FM, Olesen MK, Thakker RV. Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway. Br J Pharmacol. 2018;175(21):4083–4094. doi:10.1111/bph.14086
   PubMed Web of Science ®Google Scholar
• Ward DT, Riccardi D. New concepts in calcium-sensing receptor pharmacology and signalling. Br J Pharmacol. 2012;165(1):35–48. doi:10.1111/j.1476-5381.2011.01511.x
   PubMed Web of Science ®Google Scholar
• Tokunaga S, Kawata T. The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs. PLoS One. 2021;16(1):e0245785. doi:10.1371/journal.pone.0245785
   PubMed Web of Science ®Google Scholar